Alzheimer's disease remains one of the biggest problems of our time. There is no cure for it and all treatment options are supportive. We still can't slow the disease progression effectively.
Cortexyme, Inc. (Nasdaq: CRTX) is a San Francisco-based biotechnology company specializing in a new approach in treating Alzheimer's disease. The company's platform is based on the pathogenic cause of AD development. In this article we will try to explain the reasons for our optimism regarding this approach. Though the company has one drug candidate which is risky, we believe that it bears very